169032-22-8

Upstream product

• 169032-12-6 2-[4-(1-Ethylendioxo-4-chlorobutyl)phenyl]isobutyl acetate 
• 252022-36-9 2-[4-(1-Ethylendioxo-4-chlorobutyl)phenyl]isobutyryl amide 
• 169032-14-8 2-[4-(1-Ethylendioxo-4-chlorobutyl)phenyl]isobutyric acid 
• 169032-13-7 2-[4-(1-Ethylendioxo-4-chlorobutyl)phenyl]isobutanol 
• 169032-11-5 2-(4-(4-Chloro-1-oxo-butyl))-phenyl-2-methyl propanyl acetate 
• 101184-73-0 2-(4-bromophenyl)-2-methylpropanenitrile 
• 57625-74-8 methyl 2-methyl-2-phenylpropionate 
• 18755-52-7 (2-acetoxy-1,1-dimethylethyl)benzene 
• 2173-69-5 2-methyl-2-phenyl-propan-1-ol 
• 826-55-1 2-methyl-2-phenylpropionic acid 
• 169032-17-1 2-[4-(4-chloro-butyryl)-phenyl]-2-methyl-propionitrile 

Downstream Products

• 169032-23-9 (R)-(+)-2-[4-(1-Hydroxy-4-(4-hydroxydiphenylmethyl-1-piperidyl)butyl)phenyl]isobutyronitrile 

Relevant academic research and scientific papers

A new synthesis of carboxyterfenadine (fexofenadine) and its bioisosteric tetrazole analogs

A new synthesis of carboxyterfenadine (4), based on the conversion of a α-halo-alkylarylketone into the corresponding substituted 2-arylalkanoic ester, is described. The enantioselective synthesis of its two bioisosteric tetrazole analogs together with preliminary biological results are reported. Copyright (C) 1999 Elsevier Science S.A.

Antihistaminic compounds, process for their preparation and pharmaceutical compositions containing them

The present invention relates to terfenadine derivatives of formula where R?, which is in position 1 or 2 of the tetrazole ring, stands for H, or a linear or branched alkyl group containing from 1 to 6 carbon atoms; R? and R?, different from one another, are selected between H and OH, and their pharmaceutically acceptable salts.